Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody ... of 3.15% during 2024-2034. Nasal Polyps Market: The 7 major nasal polyps markets reached a value of US$ 68.6 Million in 2023. Looking ...

The frequency of polyp diagnoses in close relatives was strongly associated with colorectal cancer risk. Polyp history in second-degree relatives was only influential with multiple polyp diagnoses.

Polyps in the gallbladder may not cause any symptoms. Depending on the type of polyps, they can be benign, be a sign of inflammation, or potentially lead to cancer. Polyps are abnormal tissue ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

The SWIFT studies achieved their co-primary endpoints – treatment with depemokimab led to a statistically significant reduction in nasal polyp size ... the FDA expanded Dupixent’s label ...

Similarly, the ANCHOR-1 and ANCHOR-2 studies found that depemokimab effectively reduced the size and obstruction of nasal polyps compared to placebo. Kaivan Khavandi, SVP, Global Head of ...